The minutes describe blood levels
Tesamorelin copies growth hormone-releasing hormone, a natural signal. It tells the pituitary, a small gland at the base of the brain, to release growth hormone. That in turn raises IGF-1, another growth signal.
The Egrifta WR (tesamorelin) label reports a half-life of about 11 minutes in healthy people. Half-life means the time for its blood concentration to fall by half. It isn't a stopwatch for every effect that follows.
This is why I don't use blood duration as a score. A longer stay isn't automatically better. The useful question is what changed for the people studied, and whether that change lasted.
The months describe deep abdominal fat
Egrifta WR is approved to reduce excess abdominal fat in adults with HIV and lipodystrophy. With lipodystrophy, the body's usual pattern of fat storage has changed. The trials measured visceral fat: the deeper fat around abdominal organs.
That's different from overall weight loss. The label says the medicine is not for weight-loss management and has a weight-neutral effect. Less fat in one part of the body doesn't necessarily mean a lower number on the scales.
The trial follow-up also watched people switched to placebo, a dummy treatment. Their deep abdominal fat returned. A change during treatment didn't mean the change would stay after treatment stopped.
That later view matters. The first result tells us what happened under treatment. Following people afterwards tells us something else. Neither answer can be read from the half-life alone.
A narrow use, with real cautions
The label flags fluid retention along with increases in IGF-1 and blood sugar. Holding extra fluid can cause swelling and joint pain. The long-term effects of persistently high IGF-1 are unknown, and long-term cardiovascular safety hasn't been established.
The label excludes use in pregnancy or while cancer is active. A known allergy to any ingredient is another exclusion, including tesamorelin itself. Disrupted signals between the brain and pituitary also rule it out, whether from hormone failure, a pituitary tumor or surgery, head injury or radiation to the head. Approval for one use doesn't remove the need to check someone's health history.
This isn’t a general treatment for weight or ageing. The comparison page returns to the simpler lesson: minutes in blood and months of observation answer different questions.